rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
1996-7-12
|
pubmed:abstractText |
Patients with locally advanced squamous cell carcinoma of the cervix have a poor prognosis when treated by standard radiotherapy (RT) alone. Factors such as large tumor volume or nodal disease result in pelvic and distant treatment failures. Cisplatin (CDDP), a known radiosensitizer with documented activity in squamous cell carcinomas, was used in a phase II prospective study to evaluate the efficacy of combined chemo/radiotherapy in locally advanced squamous cell carcinomas of the cervix.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0090-8258
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
61
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
416-22
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8641625-Adult,
pubmed-meshheading:8641625-Aged,
pubmed-meshheading:8641625-Carcinoma, Squamous Cell,
pubmed-meshheading:8641625-Chemotherapy, Adjuvant,
pubmed-meshheading:8641625-Cisplatin,
pubmed-meshheading:8641625-Female,
pubmed-meshheading:8641625-Follow-Up Studies,
pubmed-meshheading:8641625-Humans,
pubmed-meshheading:8641625-Lymphatic Metastasis,
pubmed-meshheading:8641625-Middle Aged,
pubmed-meshheading:8641625-Neoplasm Staging,
pubmed-meshheading:8641625-Radiation-Sensitizing Agents,
pubmed-meshheading:8641625-Radiotherapy, Adjuvant,
pubmed-meshheading:8641625-Survival Analysis,
pubmed-meshheading:8641625-Treatment Outcome,
pubmed-meshheading:8641625-Uterine Cervical Neoplasms
|
pubmed:year |
1996
|
pubmed:articleTitle |
Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|